Cargando…
A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge
BACKGROUND: Marburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as demonstrated by its high associated mortality rate (23–90%) and recent emergence in West Africa for the first time. Although a recombinant vesicular stomatitis virus (rVSV)-based vaccine (Ervebo) is...
Autores principales: | Woolsey, Courtney, Cross, Robert W., Agans, Krystle N., Borisevich, Viktoriya, Deer, Daniel J., Geisbert, Joan B., Gerardi, Cheryl, Latham, Theresa E., Fenton, Karla A., Egan, Michael A., Eldridge, John H., Geisbert, Thomas W., Matassov, Demetrius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182267/ https://www.ncbi.nlm.nih.gov/pubmed/35622847 http://dx.doi.org/10.1371/journal.pntd.0010433 |
Ejemplares similares
-
Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
por: Woolsey, Courtney, et al.
Publicado: (2018) -
Immune correlates of postexposure vaccine protection against Marburg virus
por: Woolsey, Courtney, et al.
Publicado: (2020) -
Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus
por: Mire, Chad E., et al.
Publicado: (2015) -
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
por: Foster, Stephanie L., et al.
Publicado: (2022) -
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates
por: Cross, Robert W., et al.
Publicado: (2021)